Skip to content

Neuroimaging study for late-life depression

Neuroimaging study for late-life depression - Neuroimaging for late-life depression

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001228
Enrollment
60
Registered
2008-07-02
Start date
2008-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

late-life depression

Interventions

PET, MRI, Neuropsychology PET, MRI, Neuropsychology

Sponsors

National Institute of Radiological Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients 1) Age, 60-84 years 2) Diagnosis, major depressive disorder as defined by the criteria of DSM-IV-TR 3) Subjects who have the ability to provide informed consent Inclusion criteria for normal controls 1) Age, 60-84 years 2) Mini-mental state examination score, >23 points 3) No current or past history of psychiatric disorders and no current medical conditions 4) Subjects who have the ability to provide informed consent 5) Subjects who are judged by researchers as suitable for participation in the study

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients 1) Serious suicidal ideation or behavior 2) Mini-mental state examination score at screening, <=23 points 3) Co-morbid other psychiatric disorders including drug dependence 4) Existence of brain organic disease, including current or past history of cerebrovascular disease, Parkinson's disease, and other related disorders 5) Existence of serious medical illnesses 6) Subjects who are judged by researchers as not suitable for participation in the study

Design outcomes

Primary

MeasureTime frame
Findings of the comparison between depression patients and age- and gender-matched normal controls with regard to the following factors: PET study (serotonin-transporter binding, amyloid deposition, and glucose metabolism) Structural MRI Neuropsychology

Secondary

MeasureTime frame
Relationships between clinical symptoms or disease course and neuroimaging or neuropsychological tests

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026